Share on StockTwits

Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Shalini Sharp acquired 4,500 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, January 30th. The shares were purchased at an average price of $21.00 per share, with a total value of $94,500.00. Following the completion of the transaction, the chief financial officer now directly owns 84,255 shares of the company’s stock, valued at approximately $1,769,355. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 7.69% on Monday, hitting $39.00. The stock had a trading volume of 498,216 shares. Ultragenyx Pharmaceutical has a 52-week low of $38.52 and a 52-week high of $47.99. The stock has a 50-day moving average of $40.6 and a 200-day moving average of $40.6. The company’s market cap is $144.4 million.

Ultragenyx Pharmaceutical Inc is a development-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.